IL310523A - 5-hydroxytryptophan gastroretentive dosage forms - Google Patents

5-hydroxytryptophan gastroretentive dosage forms

Info

Publication number
IL310523A
IL310523A IL310523A IL31052324A IL310523A IL 310523 A IL310523 A IL 310523A IL 310523 A IL310523 A IL 310523A IL 31052324 A IL31052324 A IL 31052324A IL 310523 A IL310523 A IL 310523A
Authority
IL
Israel
Prior art keywords
htp
carbidopa
dosage form
modified release
tablet
Prior art date
Application number
IL310523A
Other languages
English (en)
Hebrew (he)
Inventor
Jacob Pade Ramsoe Jacobsen
Bret Berner
Wu Lin
Ching Sieu Tay
Original Assignee
Evecxia Therapeutics Inc
Jacob Pade Ramsoe Jacobsen
Bret Berner
Wu Lin
Ching Sieu Tay
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evecxia Therapeutics Inc, Jacob Pade Ramsoe Jacobsen, Bret Berner, Wu Lin, Ching Sieu Tay filed Critical Evecxia Therapeutics Inc
Publication of IL310523A publication Critical patent/IL310523A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL310523A 2021-07-30 2022-07-29 5-hydroxytryptophan gastroretentive dosage forms IL310523A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163227915P 2021-07-30 2021-07-30
PCT/US2022/038914 WO2023009841A1 (en) 2021-07-30 2022-07-29 5-hydroxytryptophan gastroretentive dosage forms

Publications (1)

Publication Number Publication Date
IL310523A true IL310523A (en) 2024-03-01

Family

ID=83049744

Family Applications (1)

Application Number Title Priority Date Filing Date
IL310523A IL310523A (en) 2021-07-30 2022-07-29 5-hydroxytryptophan gastroretentive dosage forms

Country Status (14)

Country Link
US (2) US11752107B2 (https=)
EP (1) EP4362919A1 (https=)
JP (1) JP2024528125A (https=)
KR (1) KR20240039030A (https=)
CN (1) CN116801868A (https=)
AU (1) AU2022320730A1 (https=)
BR (1) BR112024001927A2 (https=)
CA (1) CA3226223A1 (https=)
CL (1) CL2024000271A1 (https=)
CO (1) CO2024002256A2 (https=)
IL (1) IL310523A (https=)
MX (1) MX2024001390A (https=)
WO (1) WO2023009841A1 (https=)
ZA (1) ZA202401725B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12409163B2 (en) 2021-07-30 2025-09-09 Evecxia Therapeutics, Inc. Method of enhancing 5-hydroxytryptophan (5-HTP) exposure
US11779567B2 (en) 2021-10-14 2023-10-10 Evecxia Therapeutics, Inc. Method for optimizing 5-hydroxytryptamine function in the brain for therapeutic purposes
WO2024148354A1 (en) * 2023-01-06 2024-07-11 Evecxia Therapeutics, Inc. A method of enhancing 5-hydroxytryptophan (5-htp) exposure
WO2025042927A2 (en) * 2023-08-24 2025-02-27 Merck Sharp & Dohme Llc Sustained-release formulations for poorly permeable cyclic peptides

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4140755A (en) 1976-02-13 1979-02-20 Hoffmann-La Roche Inc. Sustained release tablet formulations
US4191184A (en) 1977-01-06 1980-03-04 Carlisle Jeffrey A Intravenous infusion regulation system with reciprocal metering means
US4658038A (en) 1982-10-07 1987-04-14 Research Foundation For Mental Hygiene, Inc. N-acylated 5-hydroxytryptophan amide derivatives
IL87710A (en) 1987-09-18 1992-06-21 Ciba Geigy Ag Covered floating retard form for controlled release in gastric juice
FR2654931B1 (fr) * 1989-11-24 1993-08-27 Trouillas Paul Compositions pharmaceutiques possedant une activite sur l'ataxie et les troubles de l'equilibre, cerebelleux ou autres, de toutes origines, comprenant l'association de l-5-hydroxytryptophane et de carbidopa.
IT1282650B1 (it) * 1996-02-19 1998-03-31 Jagotec Ag Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici
CA2290624C (en) 1997-06-06 2006-12-05 John W. Shell Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
IN186245B (https=) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
EP1063973B1 (en) 1998-03-19 2016-11-16 Bristol-Myers Squibb Company Biphasic controlled release delivery system for high solubility pharmaceuticals and method
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US7674480B2 (en) 2000-06-23 2010-03-09 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US20060013875A1 (en) 2002-05-29 2006-01-19 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
US7094427B2 (en) 2002-05-29 2006-08-22 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
BR0314804A (pt) * 2002-09-28 2005-08-02 Mcneil Ppc Inc Forma de dosagem de liberação modificada
EP1542662A1 (en) 2002-09-28 2005-06-22 McNEIL-PPC, INC. Immediate release dosage form comprising shell having openings therein
AU2003293423A1 (en) 2002-12-06 2004-06-30 Xenoport, Inc. Carbidopa prodrugs and uses thereof
ITMI20041689A1 (it) 2004-09-01 2004-12-02 Bojidar Mihaylov Stankov Nuove formulazioni di rilascio controllato contenenti 5-idrossitriptofano e triptofano
US20080268045A1 (en) 2006-11-09 2008-10-30 Proprius Pharmaceuticals, Inc. Sustained release methotrexate formulations and methods of use thereof
KR20080076382A (ko) 2007-02-15 2008-08-20 (주)아모레퍼시픽 실로스타졸의 제어방출 제제 및 그 제조방법
EP1980743B1 (en) 2007-04-10 2015-09-09 Nissan Motor Co., Ltd. Fuel pump driving device
US8969400B2 (en) 2007-10-01 2015-03-03 Duke University Pharmaceutical compositions of 5-hydroxytryptophan and serotonin-enhancing compound
KR101601649B1 (ko) 2008-04-18 2016-03-09 인텍 파마 리미티드 카르비도파／레보도파 위체류 약물 전달
ZA200903854B (en) 2008-06-19 2011-02-23 Univ Of The Witwatesrand Johannesburg A gastroretentive pharmaceutical dosage form
JP2012500221A (ja) 2008-08-15 2012-01-05 ディポメド，インコーポレイティド Ｃｎｓ障害の処理及び予防のための胃保持性医薬組成物
WO2011146611A1 (en) 2010-05-18 2011-11-24 Abon Pharmaceuticals, Llc Modified gastroretentive drug delivery system for amine drugs
US20130078290A1 (en) * 2010-06-01 2013-03-28 Rubicon Research Private Limited Gastroretentive Dosage Forms Of GABA Analogs
EP2629615B1 (en) 2010-10-22 2018-10-10 Duke University Slow-release formulations of 5-hydroxytryptophan as an adjunct to pro-serotonergic therapies
CN103554005A (zh) 2013-11-22 2014-02-05 长沙理工大学 一种左旋5-羟基色氨酸的简便合成新方法
US20170266112A1 (en) 2014-06-11 2017-09-21 Massachusetts Institute Of Technology Residence structures and related methods
HK1258050A1 (zh) 2015-10-23 2019-11-01 Lyndra Therapeutics, Inc. 用於治疗剂缓释的胃驻留系统及其使用方法
BR112020015068A2 (pt) 2018-01-29 2021-01-05 Duke University Composições e métodos de melhoramento de biodisponibilidade de 5-hidroxitriptofano
CN112469400A (zh) * 2018-06-19 2021-03-09 新加坡国立大学 对于各种适应症的生物利用度更佳的5-羟色氨酸(5-htp)制剂
EP3820468A4 (en) * 2018-07-11 2022-03-23 Duke University Use of sustained-release 5-hydroxytryptophan in treating gastrointestinal disorders

Also Published As

Publication number Publication date
JP2024528125A (ja) 2024-07-26
BR112024001927A2 (pt) 2024-04-30
WO2023009841A1 (en) 2023-02-02
KR20240039030A (ko) 2024-03-26
CA3226223A1 (en) 2023-02-02
US11752107B2 (en) 2023-09-12
CL2024000271A1 (es) 2024-08-16
US20230047338A1 (en) 2023-02-16
US20240108582A1 (en) 2024-04-04
EP4362919A1 (en) 2024-05-08
CO2024002256A2 (es) 2024-03-18
CN116801868A (zh) 2023-09-22
ZA202401725B (en) 2025-08-27
AU2022320730A1 (en) 2024-03-14
MX2024001390A (es) 2024-05-17

Similar Documents

Publication Publication Date Title
US11752107B2 (en) 5-hydroxytryptophan gastroretentive dosage forms
US10166207B2 (en) Acamprosate formulations, methods of using the same, and combinations comprising the same
US20210361566A1 (en) Formulations of 5-hydroxy tryptophan (5-htp) for better bioavailability for various indications
MX2008010578A (es) Formulacion de niacina de bajo enrojecimiento.
AU2014350135B2 (en) Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
WO2016062182A1 (zh) 一种普瑞巴林缓释制剂
WO2015051747A1 (zh) 一种普拉克索的缓释片剂与其制备方法及其用途
US12409163B2 (en) Method of enhancing 5-hydroxytryptophan (5-HTP) exposure
US20230285342A1 (en) Compositions and methods
WO2024148354A1 (en) A method of enhancing 5-hydroxytryptophan (5-htp) exposure
US20220362191A1 (en) Compositions and methods
EP2386302A1 (en) A controlled release pharmaceutical dosage form of trimetazidine and processes for the preparation thereof
TW201834643A (zh) 包含鹽酸依托必利之速釋和緩釋藥物製劑
HK40097568A (zh) 5-羟色氨酸胃滞留剂型
JP2025514428A (ja) ピルフェニドンの経口用持続放出性固形製剤
TW201626990A (zh) 含有褪黑激素和舍曲林的口服複合錠劑
MD4032530T2 (ro) Compoziție de furazidină cu eliberare prelungită